Get Started in Minutes
How Ultomiris Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Ultomiris?
Ultomiris (generic name: ravulizumab) is a type of medication called monoclonal antibodies, similar to antibodies that our bodies make to protect us when an unwanted substance enters our bodies. In the case of Ultomiris, the antibody is humanized, which means its protein sequences have been modified to increase its similarity to those produced naturally in our bodies, making it safe for human administration.
Serious meningococcal infection risk:
Ultomiris has a US Black Box Warning due to the possibility of causing serious meningococcal infection:
“Life-threatening meningococcal infections/sepsis have occurred in patients treated with Ultomiris. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.
Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Ultomiris, unless the risks of delaying Ultomiris therapy outweigh the risk of developing a meningococcal infection.
Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.
Ultomiris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).”
What is Ultomiris Used For?
Ultomiris is used for the treatment of:
- Atypical hemolytic uremic syndrome (aHUS), which is a disease that mainly affects kidney function. There is no specific age group for when this condition may occur. It can cause blood clotting to happen abnormally in the small blood vessels of the kidneys, which in turn could cause serious medical problems if blood flow becomes restricted or blocked.
- Myasthenia gravis (MG), which is a chronic autoimmune disorder in which the body’s own antibodies start attacking and destroying the connection that is responsible for communication between nerves and muscles. This results in weakness of the skeletal muscles. Myasthenia gravis generally affects voluntary muscles of the body, mainly those controlling the limbs, mouth, throat, and eyes.
- Paroxysmal nocturnal hemoglobinuria (PNH), which is a rare, acquired, life-threatening disease of the blood. The disease is characterized by premature destruction of red blood cells, blood clots, and impaired bone marrow function. PNH is closely related to aplastic anemia.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Ultomiris Side Effects
- Upper respiratory tract infection
- Abdominal pain
- Urinary tract infection
- Infusion-related reaction
- Joint stiffness
- Back pain
- Pain in the arms or legs
- Antibody development
- Infection: meningococcal infection, sepsis
- Hyperthermia (an abnormally high body temperature, which needs immediate treatment)
Directions for Use
Ultomiris dosing is based on body weight.
Treatment starts with a loading dose, then after 2 weeks, a maintenance dose is administered and then repeated every 8 weeks (4 weeks in some cases with pediatric patients).
Ultomiris is first diluted, then administered intravenously using a catheter that is inserted into the vein. Infusion is done over 36 minutes to 3.5 hours (depending on the dose to be given and the patient’s body weight). Infusions are followed by a 1-hour monitoring time for any signs or symptoms of an infusion reaction.
Ultomiris is only available through a REMS program due to the increased risk of life-threatening meningococcal infections, which can lead to death. Patients must receive the meningococcal vaccine at least 2 weeks before the first dose if they are not already vaccinated.